|Bid||37.50 x 1400|
|Ask||42.99 x 1000|
|Day's Range||38.70 - 42.47|
|52 Week Range||26.17 - 50.05|
|Beta (3Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.67|
Yahoo Finance's Julie Hyman highlights today's stocks on the move in midday trading.
The deal between Arena Pharmaceuticals (NASDAQ:ARNA) and United Therapeutics has to do with the former’s ralinepag. The deal that has Arena Pharmaceuticals stock skyrocketing today is for the exclusive worldwide develop, manufacture and commercialize rights for ralinepag. This has United Therapeutics making an upfront payment of $800 million for those rights.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment, ralinepag. The two companies said in a statement the deal for Arena's late-stage experimental treatment also includes milestone payments of up to $400 million based on certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag, the companies said.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies have entered into a global license agreement for Arena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Under the terms of the agreement, Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag.
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018.
- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD - Olorinab positive Phase 2a data for the treatment of pain associated with Crohn's disease; all ...
Jim Cramer said "That train has left the station. In this daily bar chart of ARNA, below, we can see a large sideways trading range with neutral or mixed technical signals. The Moving Average Convergence Divergence (MACD) oscillator recently crossed to the upside from below the zero line - this is a signal to cover shorts.
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update ...
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.